Analysed SHANGHAI JUNSHI BIOSCIENCE-H (SHJBF:OTCMKTS) News Sources
Junshi Biosciences Announces FDA’s Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients
17-10-2025
yahoo.com
Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis
05-12-2025
yahoo.com
Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026
20-04-2026
yahoo.com
Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma
21-05-2026
yahoo.com
Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC
27-05-2026
yahoo.com
Junshi Biosciences Enters Licensing Collaboration with Fosun Wanbang on Roconkibart (IL-17A)
02-07-2026
yahoo.com
Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC
21-07-2026
yahoo.com
What is the current price of SHANGHAI JUNSHI BIOSCIENCE-H (SHJBF:OTCMKTS)?
The current price of SHANGHAI JUNSHI BIOSCIENCE-H (SHJBF:OTCMKTS) is $0.
SHANGHAI JUNSHI BIOSCIENCE-H (SHJBF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of SHANGHAI JUNSHI BIOSCIENCE-H (SHJBF:OTCMKTS) since the previous trading day is $None.
SHANGHAI JUNSHI BIOSCIENCE-H (SHJBF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of SHANGHAI JUNSHI BIOSCIENCE-H (SHJBF:OTCMKTS) since the previous trading day is None%.
What is the most recent average sentiment score for SHANGHAI JUNSHI BIOSCIENCE-H (SHJBF:OTCMKTS)?
The most recent average sentiment score for SHANGHAI JUNSHI BIOSCIENCE-H (SHJBF:OTCMKTS) is 60 out of 100.
What is the most recent average sentiment for SHANGHAI JUNSHI BIOSCIENCE-H (SHJBF:OTCMKTS)?
The most recent sentiment for SHANGHAI JUNSHI BIOSCIENCE-H (SHJBF:OTCMKTS) is .
SEC-8K** Filing Available For SHANGHAI JUNSHI BIOSCIENCE-H (SHJBF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.